These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38688914)

  • 1. Harnessing naturally occurring mutations for T-cell therapy: a potential new avenue to enhance treatment efficacy.
    Hiltensperger M; Ruland J; Schober K
    Signal Transduct Target Ther; 2024 Apr; 9(1):117. PubMed ID: 38688914
    [No Abstract]   [Full Text] [Related]  

  • 2. Naturally occurring T cell mutations enhance engineered T cell therapies.
    Garcia J; Daniels J; Lee Y; Zhu I; Cheng K; Liu Q; Goodman D; Burnett C; Law C; Thienpont C; Alavi J; Azimi C; Montgomery G; Roybal KT; Choi J
    Nature; 2024 Feb; 626(7999):626-634. PubMed ID: 38326614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
    Zhang PF; Xie D
    Front Immunol; 2024; 15():1362133. PubMed ID: 38558812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy for cancer: harnessing the T cell response.
    Restifo NP; Dudley ME; Rosenberg SA
    Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Companion vaccines for CAR T-cell therapy: applying basic immunology to enhance therapeutic efficacy.
    E Snook A
    Future Med Chem; 2020 Aug; 12(15):1359-1362. PubMed ID: 32597219
    [No Abstract]   [Full Text] [Related]  

  • 6. Redirecting the immune response: role of adoptive T cell therapy.
    Mondino A; Dardalhon V; Hess Michelini R; Loisel-Meyer S; Taylor N
    Hum Gene Ther; 2010 May; 21(5):533-41. PubMed ID: 20201627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
    Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S
    Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene-modified T cell therapy].
    Ikeda H
    Nihon Rinsho; 2017 Feb; 75(2):275-280. PubMed ID: 30562864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoprotective Encapsulation of Individual Jurkat T Cells within Durable TiO
    Youn W; Ko EH; Kim MH; Park M; Hong D; Seisenbaeva GA; Kessler VG; Choi IS
    Angew Chem Int Ed Engl; 2017 Aug; 56(36):10702-10706. PubMed ID: 28544545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell therapy for cervical cancer.
    Cancer Discov; 2014 Aug; 4(8):862. PubMed ID: 25092728
    [No Abstract]   [Full Text] [Related]  

  • 11. [Historical perspectives and future directions of gene-modified T-cell therapy].
    Akatsuka Y
    Rinsho Ketsueki; 2016; 57(10):2241-2249. PubMed ID: 27795536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation.
    Basso S; Compagno F; Zelini P; Giorgiani G; Boghen S; Bergami E; Bagnarino J; Siciliano M; Del Fante C; Luppi M; Zecca M; Comoli P
    Front Immunol; 2020; 11():567531. PubMed ID: 33178192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
    Yin Q; Tang J; Zhu X
    Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T cell therapy seeks strategies to harness cytokine storm.
    DeFrancesco L
    Nat Biotechnol; 2014 Jul; 32(7):604. PubMed ID: 25004212
    [No Abstract]   [Full Text] [Related]  

  • 15. First Chimeric Antigen Receptor T-Cell Therapy Approved.
    Brower V
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29106609
    [No Abstract]   [Full Text] [Related]  

  • 16. Fine-tuning the effects of T-cell therapy.
    Cancer Discov; 2014 Feb; 4(2):137. PubMed ID: 24501286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell therapy targets glioblastoma.
    Cancer Discov; 2015 May; 5(5):458. PubMed ID: 25783861
    [No Abstract]   [Full Text] [Related]  

  • 18. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene editing to enhance the efficacy of cancer cell therapies.
    Murty T; Mackall CL
    Mol Ther; 2021 Nov; 29(11):3153-3162. PubMed ID: 34673274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell design: a long road ahead.
    The Lancet Haematology
    Lancet Haematol; 2018 Mar; 5(3):e95. PubMed ID: 29499769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.